Evidence map›Paper›PMID 31384715›Full record

ArticleJournal of the Endocrine Society2019

Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate.

Leo Turner, Lam P Ly, Reena Desai, Gurmeet K S Singh, Timothy D Handelsman, Sasha Savkovic, Carolyn Fennell, Veena Jayadev, Ann Conway, David J Handelsman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Endocrine Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Medical transition for gender diverse patients.Current obstetrics and gynecology reports · 2020
    Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Leo TurnerAndrology Department, Concord Hospital, Sydney, NSW, Australia.
Lam P LyAndrology Department, Concord Hospital, Sydney, NSW, Australia.
Reena DesaiAndrology Department, Concord Hospital, Sydney, NSW, Australia.
Gurmeet K S SinghANZAC Research Institute, University of Sydney, Sydney, NSW, Australia.
Timothy D HandelsmanAndrology Department, Concord Hospital, Sydney, NSW, Australia.
Sasha SavkovicAndrology Department, Concord Hospital, Sydney, NSW, Australia.
Carolyn FennellAndrology Department, Concord Hospital, Sydney, NSW, Australia.
Veena JayadevAndrology Department, Concord Hospital, Sydney, NSW, Australia.
Ann ConwayAndrology Department, Concord Hospital, Sydney, NSW, Australia.
David J HandelsmanAndrology Department, Concord Hospital, Sydney, NSW, Australia.ORCID 0000-0002-4200-7476

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextCan injectable testosterone undecanoate (TU) be administered effectively and acceptably by the subcutaneous (SC) route?

objectiveTo investigate the acceptability and pharmacokinetics (PK) of SC injection of TU.

designRandomized sequence, crossover clinical study of SC vs IM TU injections.

settingAmbulatory clinic of an academic andrology center.

participantsTwenty men (11 hypogonadal, 9 transgender men) who were long-term users of TU. injections.

resultsPain was greater after SC compared with IM injection 24 hours (but not immediately) after injection but both routes were equally acceptable. Ultimately 11 preferred IM, 6 preferred SC, and 3 had no preference. The DBS-based PK analysis of serum testosterone revealed a later time of peak testosterone concentration after SC vs IM injection (8.0 vs 3.3 days) but no significant route differences in model-predicted peak testosterone concentration (8.4 vs 9.6 ng/mL) or mean resident time (183 vs 110 days). The PK of venous serum testosterone, DHT, and E

conclusionsWe conclude that SC TU injection is acceptable but produces greater pain 24 hours after injection that may contribute to the overall majority preference for the IM injection. The PK of testosterone, DHT, or E

Indexed as

pharmacokineticspharmacologyquality of lifesubcutaneoustestosterone

Identifiers

PMID31384715
PMCPMC6676071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.